nach oben

Rheumatology International

Erschienen in:

01.02.2009 | Original Article

Targeting the CD134–CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis

verfasst von: Yan-bin Zhou, Ren-gao Ye, You-ji Li, Can-mao Xie

Erschienen in: Rheumatology International | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Lupus nephritis (LN) is characterized by an increased upregulation of Th1. This study was undertaken to evaluate the role of CD134 in cytokine production in peripheral blood mononuclear cells (PBMCs) from subjects with LN. Percentages of IFN-γ- (Th1), IL-4-, and IL-10- (Th2) producing cells within the PBMC CD4+ T cell population of LN subjects were found to be higher than those of healthy subjects. Stimulation of PBMC from LN subjects with anti-CD3 ε mAb/rIL-2 resulted in further increases in cytokine production. Stimulation in the presence of anti-CD134 mAb resulted in reduced IL-4 and IL-10 production; however, it also resulted in increased IFN-γ production. Stimulation in the presence of the fusion protein rhCD134:Fc resulted in decreased production of all three cytokines. The possibilities that anti-CD134 therapy may control the extent of IL-4- and IL-10-mediated damage in active LN and that rhCD134:Fc therapy may prevent occurrence of LN are discussed.

Weinberg AD, Evans DE, Thalhofer C, Shi T, Prell RA (2004) The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J Leukoc Biol 75:962–972. doi:10.1189/jlb.1103586 PubMedCrossRef

Watts TH (2005) TNF/TNFR family members in costimulation of T cell responses. Annu Rev Immunol 23:23–68. doi:10.1146/annurev.immunol.23.021704.115839 PubMedCrossRef

Weinberg AD (2002) OX40: targeted immunotherapy—implications for tempering autoimmunity and enhancing vaccines. Trends Immunol 23:102–109. doi:10.1016/S1471-4906(01)02127-5 PubMedCrossRef

Ohshima Y, Yang LP, Uchiyama T et al (1998) OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4+ T cells into high IL-4 producing effectors. Blood 92:3338–3345PubMed

Akiba H, Miyahira Y, Atsuta M, Takeda K, Nohara C, Futagawa T et al (2000) Critical contribution of OX40 ligand to T helper cell type 2 differentiation in experimental leishmaniasis. J Exp Med 191:375–380. doi:10.1084/jem.191.2.375 PubMedCrossRef

Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten Berge IJ, Weening JJ (2000) Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 11:1426–1438PubMed

Tucci M, Calvani N, Richards HB, Quatraro C, Silvestris F (2005) The interplay of chemokines and dendritic cells in the pathogenesis of lupus nephritis. Ann N Y Acad Sci 1051:421–432. doi:10.1196/annals.1361.084 PubMedCrossRef

Arringer M, Smolen JS (2005) Cytokine expression in lupus kidneys. Lupus 14:13–18. doi:10.1191/0961203305lu2053oa CrossRef

Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK et al (2007) Intrarenal cytokine gene expression in lupus nephritis. Ann Rheum Dis 66:886–892. doi:10.1136/ard.2006.063123 PubMedCrossRef

10.

Nakashima H, Akahoshi M, Masutani K (2006) Th1/Th2 balance of SLE patients with lupus nephritis. Rinsho Byori 54:706–713PubMed

11.

Higgins LM, McDonald SA, Whittle N et al (1999) Regulation of T cell activation in vitro and in vivo by targeting the OX40-OX40 ligand interaction: amelioration of ongoing inflammatory bowel disease with an OX40-IgG fusion protein, but not with an OX40 ligand-IgG fusion protein. J Immunol 162:486–493PubMed

12.

Arch RH, Thompson CB (1998) 4–1 BB and OX40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor κB. Mol Cell Biol 18:558–565PubMed

13.

Odobasic D, Kitching AR, Tipping PG, Holdsworth SR (2005) CD80 and CD86 costimulatory molecules regulate crescentic glomerulonephritis by different mechanisms. Kidney Int 68:584–594. doi:10.1111/j.1523-1755.2005.00436.x PubMedCrossRef

14.

Patschan S, Dolff S, Kribben A, Durig J, Patschan D, Wilde B et al (2006) CD134 expression on CD4+ T cells is associated with nephritis and disease activity in patients with systemic lupus erythematosus. Clin Exp Immunol 145:235–242. doi:10.1111/j.1365-2249.2006.03141.x PubMedCrossRef

15.

Ye RG (2000) Systemic lupus erythematosus. In: Textbook of internal medicine. People’s Publishing House of Public Health, Beijing City, pp 909–915

16.

Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 35:630–640. doi:10.1002/art.1780350606 PubMedCrossRef

17.

Chang AE, Aruga A, Cameron MJ, Sondak VK, Normolle DP, Fox BA et al (1997) Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15:796–807PubMed

18.

Huang H, Yu H, Xiong SD (2001) Enhancement of anti-CD4 mAb on anti-tumor activity of tumor-specific T cells activated by rIL-2 and anti-CD3 mAb. J Cell Mol Immunol 17:160–164

19.

Yi-wei C, Fox BA (2001) Induction of tumor-specific Th1 cell response in vitro by anti-OX-40 and anti-IL-4. Shanghai J Immunol 21:148–150 Chinese

20.

Zhou YB, Li YJ, Wu YH (2006) Study on the levels in the serum and mRNA expression in PBMCs of interleukin-10 and interferon-γ of patients with lupus nephritis. China J Mod Med 16:529–532 Chinese

21.

Pillet MJ, Mempel TR (2008) Regulation of T-cell migration and effector functions: insight in in vivo imaging studies. Immunol Rev 221:107–129. doi:10.1111/j.1600-065X.2008.00584.x CrossRef

22.

Weinberg AD, Thalhofer C, Morris N, Walker JM, Seiss D, Wong S et al (1997) Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother 29:575–585. doi:10.1097/01.cji.0000211319.00031.fc CrossRef

23.

Totsuka T, Kanai T, Uraushihara K, Iiyama T, Yamazaki M, Akiba H et al (2003) Therapeuetic effect of anti-OS40L and anti-TNF-alpha MAbs in a murine model of chronic colitis. Am J Physiol Gastrointest Liver Physiol 284:G595–G603PubMed

24.

Yuan X, Salama AD, Dong V, Schmitt I, Najafian N, Chandraker A et al (2003) The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J Immunol 170:2949–2955PubMed

25.

Blazar BR, Sharpe AH, Chen AI, Panoskaltsis-Mortari A, Lees C, Akiba H, Yagita H, Killeen N, Taylor PA (2003) Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood 101:3741–3748PubMedCrossRef

26.

Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S et al (2000) Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 30:2815–2823. doi:10.1002/1521-4141(200010)30:10<2815::AID-IMMU2815>3.0.CO;2-#PubMedCrossRef

27.

Taylor L, Bachler M, Duncan I, Keen S, Fallon R, Mair C et al (2002) In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions. J Leukoc Biol 72:522–529PubMed

28.

Curry AJ, Chikwe J, Smith XG, Cai M, Schwarz H, Bradley JA et al (2004) OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival. Transplantation 78:807–814. doi:10.1097/01.TP.0000131670.99000.54 PubMedCrossRef

29.

Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE (2005) Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 103:156–164PubMedCrossRef

30.

Morris NP, Peters C, Montler R, Hu HM, Curti BD, Urba WJ et al (2007) Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol 44:3112–3121. doi:10.1016/j.molimm.2007.02.004 PubMedCrossRef

31.

Gramaglia I, Weinberg AD, Lemon M et al (1998) OX-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell reponses. J Immunol 161:6510–6517PubMed

32.

Weinberg AD, Rivera MM, Prell RJ et al (2000) Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol 164:2160–2169PubMed

33.

Rogers PR, Song J, Gramaglia I et al (2001) OX40 promotes Bcl-XL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. Immunity 15:445–455. doi:10.1016/S1074-7613(01)00191-1 PubMedCrossRef

34.

Maxwell JR, Weinberg A, Prell RA et al (2000) Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inbibiting peripheral deletion. J Immunol 164:107–112PubMed

35.

Li M, Zhang Y (2006) Effect of antibody to CD134 on perforin-mediated cytolysis in human peripheral blood mononuclear cells. Hybridoma 25:145–153. doi:10.1089/hyb.2006.25.145 PubMedCrossRef

36.

Takeda I, Ine S, Killeen N et al (2004) Distinct roles for the OX40-OX40 ligand interaction in regulatory and nonregulatory T cells. J Immunol 172:3580–3589PubMed

37.

Agarwal SK, Marshall GD Jr (2001) Dexamethasone promotes type 2 cytokine production primarily through inhibition of type 1 cytokines. J Interferon Cytokine Res 21:147–155. doi:10.1089/107999001750133159 PubMedCrossRef

38.

Amit M, Mor A, Weissgarten J, Rosenberg R, Ramot Y, Wysenbeek AJ et al (2000) Inactive systemic lupus erythematosus is associated with a normal stimulated Th(1)/Th(2) cytokine secretory pattern. Cytokine 12:1405–1408. doi:10.1006/cyto.2000.0724 PubMedCrossRef

39.

Akahoshi M, Nakashima H, Tanaka Y, Kohsaka T, Nagano S, Ohgami E et al (1999) Th1/Th2 balance of peripheral T helper cells in systemic lupus erythematosus. Arthritis Rheum 42:1644–1648. doi:10.1002/1529-0131(199908)42:8<1644::AID-ANR12>3.0.CO;2-LPubMedCrossRef

Titel: Targeting the CD134–CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis
verfasst von: Yan-bin Zhou
Ren-gao Ye
You-ji Li
Can-mao Xie
Publikationsdatum: 01.02.2009
Verlag: Springer-Verlag
Erschienen in: Rheumatology International / Ausgabe 4/2009
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-008-0697-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Targeting the CD134–CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2009

Bone mineral density in Indian women with rheumatoid arthritis

The importance of severity of arthrosis for the reliability of bone mineral density measurement in women

New lines in therapy of Raynaud’s phenomenon

Efficacy of tacrolimus in infliximab-refractory progressive rheumatoid arthritis

Clinical utility of cardiac magnetic resonance imaging in Churg–Strauss syndrome: case report and review of the literature

NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin